1. Home
  2. HMY vs RGEN Comparison

HMY vs RGEN Comparison

Compare HMY & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Gold Mining Company Limited

HMY

Harmony Gold Mining Company Limited

HOLD

Current Price

$14.30

Market Cap

12.7B

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$110.25

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HMY
RGEN
Founded
1950
1981
Country
South Africa
United States
Employees
34350
N/A
Industry
Precious Metals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.7B
8.1B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
HMY
RGEN
Price
$14.30
$110.25
Analyst Decision
Buy
Buy
Analyst Count
2
11
Target Price
$16.00
$175.64
AVG Volume (30 Days)
4.5M
811.6K
Earning Date
02-04-2016
04-28-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
286.96
EPS
N/A
0.86
Revenue
N/A
$141,236,000.00
Revenue This Year
$40.34
$14.31
Revenue Next Year
$22.08
$14.41
P/E Ratio
$15.60
$132.98
Revenue Growth
N/A
35.10
52 Week Low
$12.57
$102.97
52 Week High
$26.04
$175.77

Technical Indicators

Market Signals
Indicator
HMY
RGEN
Relative Strength Index (RSI) 33.92 30.20
Support Level $13.53 N/A
Resistance Level $15.65 $132.51
Average True Range (ATR) 0.64 4.68
MACD -0.11 0.43
Stochastic Oscillator 18.68 2.57

Price Performance

Historical Comparison
HMY
RGEN

About HMY Harmony Gold Mining Company Limited

Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: